Myeloma News

Healio will present its fourth annual Disruptive Innovators Awards for oncology/hematology this spring.

The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.

U.S. Surgeon General Vivek Murthy, MD, MBA, issued an advisory today that includes several recommendations designed to reduce the impact of alcohol on cancer incidence and mortality.

SAN DIEGO — Anitocabtagene autoleucel exhibited durable efficacy among heavily pretreated patients with high-risk relapsed or refractory multiple myeloma, results of the phase 2 iMMagine-1 study showed.

SAN DIEGO — Patients underrepresented in pivotal trials of anti-CD19 chimeric antigen receptor T-cell therapy may still derive benefit from the treatment modality, according to a speaker at ASH Annual Meeting and Exposition.

SAN DIEGO — The increased use of AI in health care has generated tremendous excitement for its potential to guide treatment decision-making, improve outcomes and increase efficiency.

SAN DIEGO — Daratumumab monotherapy significantly delayed progression of high-risk smoldering multiple myeloma to active multiple myeloma compared with active monitoring, according to results of the randomized phase 3 AQUILA study.

SAN DIEGO — Successfully addressing financial toxicity for people with blood cancer will require substantial efforts from a variety of stakeholders, according to a speaker at ASH Annual Meeting and Exposition.

SAN DIEGO — A high-fiber plant-based diet may delay progression of certain precursor conditions to multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.